Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

Blood (2019) 134 (Supplement_1): 5423.

https://doi.org/10.1182/blood-2019-125806

Published: 2019

Journal Articles

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Blood (2018) 132 (Supplement 1): 3107.

https://doi.org/10.1182/blood-2018-99-115206

Published: 2018

Journal Articles

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Athanasios Galanopoulos, MD PhD, Evdoxia Kamouza, Christos K. Kontos, PhD, Argiris Symeonidis, MD PhD, Vassiliki Pappa, MD, Alexandra Kourakli, MD PhD, Nora-Athina Viniou, MD, Sotirios Papageorgiou, MD PhD, Charalampos Pontikoglou, Menelaos Konstantinos Papoutselis, Helen A. Papadaki, MD PhD, Eleftheria Hatzimichael, Panagiotis Zikos, Dr, Maria Dimou, Panayiotis Panayiotidis, MD PhD, Dimitrios Tsokanas, Despina Mparmparousi, Flora Kontopidou, Eleni Variami, Panagiotis Repousis, MD, Elias Poulakidas, Dimitrios Christoulas, MD, Theodoros Vassilakopoulos, MDPhD, Michael Voulgarelis, MD PhD, Aikaterini Megalakaki, Maria Kotsopoulou, Giorgos Karianakis, Despina Kaliontzi, Ioannis Adamopoulos, MD, Maria Dalekou, Anastasia Sioni, Maria Papaioannou, Dimitrios Gogos, Panagiotis Theodorou Diamantopoulos, MD PhD, Elena E. Solomou, MD, Ioannis Kotsianidis, PhD

Blood (2018) 132 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2018-99-119531

Published: 2018

Journal Articles

Myelodysplastic Syndromes/Myeloproliferative Neoplasms Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Panagiotis Theodorou Diamantopoulos, MD PhD, Ioannis Kotsianidis, PhD, Argiris Symeonidis, MD PhD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Dimitrios Gogos, Paraskevi Roussou, Helen A. Papadaki, MD PhD, Aikaterini Palla, Eleftheria Hatzimichael, Maria Dimou, Sossana Delibasi, Menelaos Konstantinos Papoutselis, Alexandra Kourakli, MD, Dimitrios Tsokanas, Niki Rougala, Panayiotis Panayiotidis, MD PhD, Nora-Athina Viniou

Blood (2017) 130 (Supplement 1): 2974.

https://doi.org/10.1182/blood.V130.Suppl_1.2974.2974

Published: 2017

Journal Articles

Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis

Efstathios Kastritis, Maria Roussou, Magdalini Migkou, Maria Gavriatopoulou, Constantinos Pamboukas, Sosana Delimpassi, Evelina Charitaki, Eurydiki Michalis, Kaladaridou Anna, Plastiras Sotirios, Dimitrios Gogos, Agrios Ioannis, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2010) 116 (21): 3048.

https://doi.org/10.1182/blood.V116.21.3048.3048

Published: 2010

Journal Articles

A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis.

Efstathios Kastritis, Maria Roussou, Magdalini Migkou, Konstantinos Pamboukas, Maria Gavriatopoulou, Dimitrios Gogos, Konstantinos Liapis, Eurydiki Michalis, Sosana Delimpasi, Erasmia Psimenou, Savvas Toumanidis, Sofocles A. Kontoyannis, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2009) 114 (22): 428.

https://doi.org/10.1182/blood.V114.22.428.428

Published: 2009

Journal Articles

AML Survival and In Vivo Progression Is Dependent On β-Catenin Signaling.

Elena K Siapati, PhD, Magda Papadaki, MSc, Zoi Kozaou, Erasmia Rouka, Evridiki Michali, MD, Dimitrios Gogos, Ioanna Savvidou, Despoina S Kyriakou, MD, PhD, Nikolaos.I. Anagnostopoulos, George Vassilopoulos, MD, PhD

Blood (2009) 114 (22): 2398.

https://doi.org/10.1182/blood.V114.22.2398.2398

Published: 2009

NARROW

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Myelodysplastic Syndromes/Myeloproliferative Neoplasms Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis

A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis.

AML Survival and In Vivo Progression Is Dependent On β-Catenin Signaling.

Email alerts

ASH Publications

American Society of Hematology

Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group

Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group

Myelodysplastic Syndromes/Myeloproliferative Neoplasms Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry

Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis

A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis.

AML Survival and In Vivo Progression Is Dependent On β-Catenin Signaling.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only